{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:30:15Z","timestamp":1790217015374,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Project of Monitoring and Evaluation of the Use of Key Clinical Drugs commissioned by the Chinese Association of Research Hospitals","award":["Y2023FH-YWPJ03"],"award-info":[{"award-number":["Y2023FH-YWPJ03"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["CFH2024-2-5012"],"award-info":[{"award-number":["CFH2024-2-5012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00228-025-03941-4","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:36:28Z","timestamp":1767432988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Construction and temporal external validation of interpretable machine-learning models for predicting tigecycline-associated hypofibrinogenemia"],"prefix":"10.1007","volume":"82","author":[{"given":"An","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"3941_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.761167","volume":"12","author":"X Shi","year":"2021","unstructured":"Shi X, Zuo C, Yu L et al (2021) Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM. Front Pharmacol 12:761167","journal-title":"Front Pharmacol"},{"issue":"2","key":"3941_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijantimicag.2015.11.011","volume":"47","author":"W Ni","year":"2016","unstructured":"Ni W, Han Y, Zhao J et al (2016) Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents 47(2):107\u201316","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"3941_CR3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","volume":"37","author":"L Zha","year":"2020","unstructured":"Zha L, Pan L, Guo J et al (2020) Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther 37(3):1049\u201364","journal-title":"Adv Ther"},{"key":"3941_CR4","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.2147\/IDR.S322803","volume":"14","author":"H HAN","year":"2021","unstructured":"HAN H, QIN W, ZHENG Y et al (2021) High-Dose versus Standard-Dose Tigecycline treatment of secondary bloodstream infections caused by extensively Drug-Resistant acinetobacter baumannii: an observational cohort study [J]. Infect Drug Resist 14:3837\u20133848","journal-title":"Infect Drug Resist"},{"issue":"1","key":"3941_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106487","volume":"59","author":"G Dimopoulos","year":"2022","unstructured":"Dimopoulos G, Almyroudi MP, Kapralos I et al (2022) Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia. Int J Antimicrob Agents 59(1):106487","journal-title":"Int J Antimicrob Agents"},{"key":"3941_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.943674","volume":"13","author":"B Leng","year":"2022","unstructured":"Leng B, Shen C, Gao T et al (2022) Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: a multicenter retrospective study in China. Front Pharmacol 13:943674","journal-title":"Front Pharmacol"},{"key":"3941_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03419-7","author":"C Ma","year":"2024","unstructured":"Ma C, Ren X, Pang N et al (2024) Incidence, characteristics, and risk factors of hypofibrinogenemia induced by generic tigecycline: a retrospective study. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03419-7","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"3941_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","volume":"76","author":"J Hu","year":"2020","unstructured":"Hu J, Xiao YH, Zheng Y et al (2020) Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients. Eur J Clin Pharmacol 76(7):913\u201322","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3941_CR9","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/jcpt.13250","volume":"45","author":"Q ZHANG","year":"2020","unstructured":"ZHANG Q, WANG J, LIU H et al (2020) Risk factors for tigecycline-induced hypofibrinogenaemia [J]. J Clin Pharm Ther 45(6):1434\u20131441","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"3941_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/10408347.2020.1793098","volume":"52","author":"M Bialkower","year":"2022","unstructured":"Bialkower M, Garnier G (2022) Fibrinogen diagnostics in major hemorrhage. Crit Rev Anal Chem 52(1):194\u2013209","journal-title":"Crit Rev Anal Chem"},{"key":"3941_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/TCRM.S302850","volume":"17","author":"J Liu","year":"2021","unstructured":"Liu J, Yan Y, Zhang F (2021) Risk factors for tigecycline-associated hypofibrinogenemia. Ther Clin Risk Manag 17:325\u201332","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"3941_CR12","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s11096-020-01072-7","volume":"42","author":"D Campany-Herrero","year":"2020","unstructured":"Campany-Herrero D, Larrosa-Garcia M, Lalueza-Broto P et al (2020) Tigecycline-associated hypofibrinogenemia in a real-world setting. Int J Clin Pharm 42(4):1184\u20139","journal-title":"Int J Clin Pharm"},{"key":"3941_CR13","doi-asserted-by":"crossref","unstructured":"GUO J, WANG S, ZHOU M et al (2023) Nomogram for the prediction of tigecycline-induced hypofibrinogenemia in Chinese population [J]. Int J Antimicrob Agents, 107062","DOI":"10.1016\/j.ijantimicag.2023.107062"},{"key":"3941_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1182644","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Cai X, Peng F et al (2023) Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone\/sulbactam therapy and other tigecycline-based combination therapies. Front Pharmacol 14:1182644","journal-title":"Front Pharmacol"},{"issue":"1","key":"3941_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-024-02694-x","volume":"24","author":"J Zhu","year":"2024","unstructured":"Zhu J, Zhao R, Yu Z et al (2024) Machine learning-based prediction model for hypofibrinogenemia after tigecycline therapy. BMC Med Inform Decis Mak 24(1):284","journal-title":"BMC Med Inform Decis Mak"},{"key":"3941_CR16","unstructured":"LUNDBERG SM, LEE S-I. F (2017) [C]"},{"issue":"6","key":"3941_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00228-023-03492-6","volume":"79","author":"H Guo","year":"2023","unstructured":"Guo H, Li P, Guo D et al (2023) Analysis of clinical characteristics and automatic monitoring of drug-induced arrhythmias in 167,546 inpatients. Eur J Clin Pharmacol 79(6):759\u201365","journal-title":"Eur J Clin Pharmacol"},{"key":"3941_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9742754","author":"C Yu","year":"2020","unstructured":"Yu C, Guo D, Yao C et al (2020) Clinical characteristics of hospitalized patients with drug-induced acute kidney injury and associated risk factors: a case-control study. Biomed Res Int. https:\/\/doi.org\/10.1155\/2020\/9742754","journal-title":"Biomed Res Int"},{"issue":"1","key":"3941_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-024-00761-7","volume":"25","author":"A Fu","year":"2024","unstructured":"Fu A, Ge F, Wang Y et al (2024) Development and internal validation of a model for predicting cefoperazone\/sulbactam-associated coagulation disorders in Chinese inpatients. BMC Pharmacol Toxicol 25(1):41","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"3941_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u20134","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3941_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825\u201330","journal-title":"Ann Intern Med"},{"issue":"30","key":"3941_CR22","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1002\/sim.3148","volume":"26","author":"W Sauerbrei","year":"2007","unstructured":"Sauerbrei W, Royston P, Binder H (2007) Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 26(30):5512\u201328","journal-title":"Stat Med"},{"issue":"11","key":"3941_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i11","volume":"36","author":"MB Kursa","year":"2010","unstructured":"Kursa MB, Rudnicki WR (2010) Feature selection with the Boruta package. J Stat Softw 36(11):1\u201313","journal-title":"J Stat Softw"},{"key":"3941_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eswa.2019.05.028","volume":"134","author":"JL Speiser","year":"2019","unstructured":"Speiser JL, Miller ME, Tooze J et al (2019) A comparison of random forest variable selection methods for classification prediction modeling. Expert Syst Appl 134:93\u2013101","journal-title":"Expert Syst Appl"},{"issue":"2","key":"3941_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.32614\/RJ-2015-018","volume":"7","author":"R Genuer","year":"2015","unstructured":"Genuer R, Poggi JM, Tuleau-Malot C (2015) VSURF: an R package for variable selection using random forests. R J 7(2):19\u201333","journal-title":"R J"},{"issue":"11","key":"3941_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002689","volume":"15","author":"E Vayena","year":"2018","unstructured":"Vayena E, Blasimme A, Cohen IG (2018) Machine learning in medicine: addressing ethical challenges. PLoS Med 15(11):e1002689","journal-title":"PLoS Med"},{"issue":"2","key":"3941_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/CCM.0000000000001571","volume":"44","author":"MM Churpek","year":"2016","unstructured":"Churpek MM, Yuen TC, Winslow C et al (2016) Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. Crit Care Med 44(2):368\u201374","journal-title":"Crit Care Med"},{"issue":"1","key":"3941_CR28","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"JB MOONS K G, ALTMAN D G, REITSMA","year":"2015","unstructured":"MOONS K G, ALTMAN D G, REITSMA JB et al (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration [J]. Ann Intern Med 162(1):W1\u201373","journal-title":"Ann Intern Med"},{"key":"3941_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.795026","volume":"11","author":"S Heber","year":"2021","unstructured":"Heber S, Pereyra D, Schrottmaier WC et al (2021) A model predicting mortality of hospitalized COVID-19 patients four days after admission: development, internal and temporal-external validation. Front Cell Infect Microbiol 11:795026","journal-title":"Front Cell Infect Microbiol"},{"key":"3941_CR30","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.2147\/DMSO.S316950","volume":"14","author":"H Zhang","year":"2021","unstructured":"Zhang H, Chen D, Shao J et al (2021) External validation of the prognostic prediction model for 4-year risk of metabolic syndrome in adults: a retrospective cohort study. Diabetes Metab Syndr Obes 14:3027\u201334","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"3941_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-023-04049-z","volume":"23","author":"C Chen","year":"2023","unstructured":"Chen C, Yin C, Wang Y et al (2023) XGBoost-based machine learning test improves the accuracy of hemorrhage prediction among geriatric patients with long-term administration of rivaroxaban. BMC Geriatr 23(1):418","journal-title":"BMC Geriatr"},{"key":"3941_CR32","doi-asserted-by":"crossref","unstructured":"TREML B, RAJSIC S, HELL T et al (2021) Progression of fibrinogen decrease during high dose Tigecycline therapy in critically ill patients: A retrospective analysis [J]. J Clin Med, 10(20)","DOI":"10.3390\/jcm10204702"},{"issue":"19","key":"3941_CR33","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1053\/euhj.1999.2207","volume":"21","author":"A WOODS","year":"2000","unstructured":"WOODS A, BRULL D J, HUMPHRIES S E et al (2000) Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6 [J]. Eur Heart J 21(19):1574\u20131583","journal-title":"Eur Heart J"},{"key":"3941_CR34","doi-asserted-by":"crossref","unstructured":"BRANDTNER A, BACHLER M (2020) FRIES D, Tigecycline interferes with fibrinogen polymerization independent of peripheral interactions with the coagulation system [J]. Antibiot (Basel), 9(2)","DOI":"10.3390\/antibiotics9020084"},{"key":"3941_CR35","doi-asserted-by":"crossref","unstructured":"G\u00f3MEZ-LECH\u00f3N CASTELLJV et al (1990) Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6 [J]. 12(5):1179\u20131186 Hepatology (Baltimore, Md)","DOI":"10.1002\/hep.1840120517"},{"issue":"2","key":"3941_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccc.2012.12.003","volume":"29","author":"RI Parker","year":"2013","unstructured":"Parker RI (2013) Coagulopathies in the PICU: DIC and liver disease. Crit Care Clin 29(2):319\u201333","journal-title":"Crit Care Clin"},{"issue":"6","key":"3941_CR37","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1055\/s-0035-1556730","volume":"41","author":"N Semeraro","year":"2015","unstructured":"Semeraro N, Ammollo CT, Semeraro F et al (2015) Coagulopathy of acute sepsis. Semin Thromb Hemost 41(6):650\u20138","journal-title":"Semin Thromb Hemost"},{"key":"3941_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijid.2022.08.014","volume":"123","author":"X Yang","year":"2022","unstructured":"Yang X, Jin L, Luo X et al (2022) Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: a retrospective cohort study. Int J Infect Dis 123:136\u201342","journal-title":"Int J Infect Dis"},{"issue":"6","key":"3941_CR39","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s11096-019-00912-5","volume":"41","author":"N Cui","year":"2019","unstructured":"Cui N, Cai H, Li Z et al (2019) Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm 41(6):1408\u201313","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"3941_CR40","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/annonc\/mdm112","volume":"18","author":"TY Halim","year":"2007","unstructured":"Halim TY, Song KW, Barnett MJ et al (2007) Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Ann Oncol 18(7):1246\u201352","journal-title":"Ann Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03941-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03941-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03941-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:39:30Z","timestamp":1771508370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03941-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3941"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03941-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved and exempted from the informed consent requirements by the ethics committee of the hospital (No. S2018-054-01). All patient data were anonymized according to the\n                      Declaration of Helsinki\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}